Semaglutide opened the door. Tirzepatide pushed it further. But the pipeline of metabolic drug candidates now in late-stage clinical trials suggests that the first generation of GLP-1 receptor agonists may eventually be viewed as early entries in a much larger story. Across pharmaceutical development programs at Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and several smaller firms, a set of next-generation compounds are producing clinical results that differ from existing options in meaningful ways — higher efficacy, oral delivery, novel receptor combinations, and attempts to address the lean mass loss that has become the most discussed limitation of current therapies.
This article surveys the most advanced candidates in the weight-management pipeline beyond semaglutide and tirzepatide. All data cited comes from published clinical trial results and regulatory filings. None of these agents are FDA-approved for weight management as of April 2026, and nothing here constitutes a recommendation for use.
Retatrutide: The Triple Agonist
Retatrutide is Eli Lilly's triple receptor agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously. While semaglutide activates one receptor and tirzepatide activates two, retatrutide adds glucagon receptor agonism — a mechanism that appears to increase energy expenditure and fat oxidation beyond what appetite suppression alone can achieve.
The TRIUMPH-4 Phase 3 trial, the first Phase 3 readout for retatrutide, enrolled 445 participants with obesity and knee osteoarthritis. Results announced in early 2026 showed that participants receiving the 12 mg dose experienced a mean body weight reduction of 28.7% over 68 weeks. The 9 mg dose produced a 26.4% mean reduction. In absolute terms, the 12 mg group lost an average of 71.2 pounds. These figures represent the highest weight reduction reported for any pharmacological agent in a Phase 3 trial to date.
Beyond weight loss, TRIUMPH-4 participants showed substantial reductions in knee osteoarthritis pain, with WOMAC pain scores improving by up to 75.8% — suggesting that the degree of weight reduction may cross a threshold where mechanical joint load drops enough to produce meaningful orthopedic benefit.
What Makes the Glucagon Component Work
Adding a glucagon agonist to a weight-loss peptide may seem counterintuitive, since glucagon is classically known for raising blood glucose. But at the doses used in retatrutide, glucagon receptor activation appears to increase resting energy expenditure and drive preferential fat mobilization. The GLP-1 component counterbalances any hyperglycemic effects, while the GIP component enhances glucose-dependent insulin secretion. The net result: the body burns more energy at rest while appetite remains suppressed.
Seven additional Phase 3 trial readouts from the TRIUMPH program are expected throughout 2026, including studies evaluating maintenance dosing strategies. Eli Lilly is expected to file for FDA approval in late 2026 or 2027, pending the complete Phase 3 data package.
Orforglipron: A Pill, Not a Peptide
Orforglipron represents a fundamentally different approach to GLP-1 receptor activation. It is a small-molecule, non-peptide GLP-1 agonist — meaning it activates the same receptor as semaglutide, but it is not a peptide. This distinction matters because orforglipron can be taken as a daily oral pill without the bioavailability challenges that limit oral peptide formulations (oral semaglutide, for instance, requires fasting and large quantities of an absorption enhancer to get a small fraction of the peptide into the bloodstream).
As a small molecule, orforglipron is chemically stable in stomach acid, does not require an absorption enhancer, and can be manufactured through conventional pharmaceutical chemistry rather than the complex recombinant or synthetic processes required for peptide production. This has implications for both patient convenience and manufacturing scalability.
Clinical Results
The Phase 3 ATTAIN-1 trial evaluated orforglipron across three doses (6 mg, 12 mg, and 36 mg) in adults with obesity or overweight without diabetes. At 72 weeks, participants on the highest dose lost a mean of 12.4% of body weight (approximately 27.3 pounds). Among those receiving 36 mg, 59.6% achieved at least 10% weight loss and 39.6% achieved at least 15%.
In ATTAIN-2, which enrolled participants with obesity and type 2 diabetes, the 36 mg dose produced a mean weight reduction of 10.5% (approximately 22.9 pounds) alongside a 1.8 percentage point reduction in HbA1c. Across the ACHIEVE trials in type 2 diabetes, orforglipron outperformed both dapagliflozin (ACHIEVE-2) and oral semaglutide (ACHIEVE-3) on primary endpoints.
These weight-loss numbers are more modest than what injectable semaglutide or tirzepatide produce. The clinical significance of orforglipron is not that it produces the most weight loss, but that it eliminates the injection barrier entirely while using a molecule that is cheaper and simpler to manufacture at scale. For patients who decline injectable therapy — and survey data consistently shows that needle aversion is a primary reason people do not initiate GLP-1 treatment — orforglipron offers a genuinely different access point.
The completion of a third successful Phase 3 trial has triggered global regulatory submissions. Eli Lilly has indicated that FDA submission for the treatment of type 2 diabetes is anticipated in 2026, with an obesity indication expected to follow.
CagriSema: Semaglutide Plus an Amylin Analog
CagriSema is Novo Nordisk's fixed-dose combination of semaglutide (the GLP-1 agonist in Ozempic and Wegovy) and cagrilintide, a long-acting amylin receptor agonist. Amylin is a hormone co-secreted with insulin from pancreatic beta cells that slows gastric emptying and promotes satiety through mechanisms distinct from GLP-1. By combining two appetite-regulating hormones with non-overlapping receptor targets, CagriSema aims to produce greater weight loss than semaglutide alone.
The Phase 3 REDEFINE program has produced notable results. In REDEFINE 1, which enrolled 3,400 participants with overweight or obesity (without diabetes) and at least one weight-related health condition, participants receiving CagriSema achieved a mean body weight reduction of 20.4% at 68 weeks, compared to 3.0% with placebo. Sixty percent of participants lost at least 20% of their body weight, and 23% lost 30% or more.
In REDEFINE 2, conducted in participants with type 2 diabetes, CagriSema produced a mean 13.7% weight reduction alongside substantial improvements in glycemic control — 73.5% of participants achieved an HbA1c below 6.5%.
Gastrointestinal side effects remained the most commonly reported adverse events, consistent with other incretin-based therapies, though the majority were mild or moderate and tended to diminish over time. The REDEFINE results were published in the New England Journal of Medicine in 2025. Novo Nordisk has submitted a New Drug Application (NDA) to the FDA, with regulatory review anticipated in 2026.
Amycretin: Novo Nordisk's Next-Generation Dual Agonist
If CagriSema combines two separate molecules in one injection, amycretin takes the concept one step further. Amycretin is a unimolecular dual agonist — a single synthetic peptide engineered to activate both GLP-1 and amylin receptors simultaneously. This is distinct from CagriSema's approach of co-formulating two separate molecules, and it may offer pharmacokinetic advantages in terms of consistent receptor activation ratios.
Phase 2 results announced in late 2025 showed that subcutaneous amycretin produced weight loss of up to 14.5% over 36 weeks in participants with type 2 diabetes, compared to 2.6% with placebo. The once-weekly injection formulation led to HbA1c reductions of 1.8 percentage points, with 89.1% of participants achieving HbA1c below 7%. An oral formulation was also tested, producing weight loss of up to 10.1% over the same period.
Novo Nordisk has advanced amycretin to Phase 3 trials, with initiation expected in 2026. If the Phase 3 program succeeds, market entry could occur in 2028 or 2029. The dual GLP-1/amylin mechanism positions amycretin as a potential successor to both semaglutide and CagriSema in Novo Nordisk's pipeline.
Survodutide: The GLP-1/Glucagon Dual Agonist
Developed by Boehringer Ingelheim and Zealand Pharma, survodutide is a dual agonist targeting both GLP-1 and glucagon receptors. While retatrutide adds glucagon agonism on top of GLP-1 and GIP, survodutide pairs GLP-1 with glucagon directly — omitting the GIP component but retaining the metabolic acceleration that glucagon receptor activation provides.
In Phase 2 studies, survodutide produced weight loss of up to 19% at 46 weeks, along with reductions in waist circumference of up to 16 cm and systolic blood pressure reductions of up to 8.6 mmHg. These results led to the launch of the Phase 3 SYNCHRONIZE program, which includes SYNCHRONIZE-1 (participants without type 2 diabetes) and SYNCHRONIZE-2 (participants with type 2 diabetes). Both are 76-week, randomized, double-blind, placebo-controlled trials.
As of April 2026, the SYNCHRONIZE Phase 3 trials are ongoing and have not yet reported topline results. The compound is also being studied for metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH), where the glucagon component may offer liver-specific benefits through enhanced hepatic fat oxidation.
The Muscle-Sparing Frontier
Across all GLP-1 based therapies, one limitation has emerged as a central concern: lean mass loss. Published analyses indicate that lean tissue accounts for roughly 26% to 40% of total weight lost during GLP-1 and GLP-1/GIP agonist therapy. While some lean mass loss is physiologically expected during any substantial weight reduction, the magnitude observed with high-efficacy agents has prompted a parallel research effort focused on preserving muscle during pharmacological weight loss.
Several approaches are in clinical development:
- Bimagrumab (anti-activin type II receptor antibody): When combined with semaglutide, bimagrumab shifted the composition of weight loss so that 92.8% of total weight lost came from fat mass, compared to 71.8% with semaglutide alone. Used by itself, bimagrumab produced weight loss that was 100% attributable to fat, with a 2.5% increase in total lean mass.
- Trevogrumab and garetosmab (anti-myostatin and anti-activin A): Regeneron's Phase 2 COURAGE trial tested these antibodies in combination with semaglutide. The rationale is that blocking myostatin — a negative regulator of muscle growth — during weight loss could counteract the catabolic signals that drive lean tissue loss. Updated analyses from this trial were presented at EASD, with results suggesting improved body composition quality.
- Selective androgen receptor modulators (SARMs): The Phase 2b QUALITY trial evaluated enobosarm in combination with semaglutide. Participants receiving enobosarm lost 71% less lean mass compared to semaglutide alone, while fat loss was preserved.
None of these muscle-preservation strategies have reached Phase 3 in the context of GLP-1 combination therapy as of April 2026. But the data from early-stage trials has established that the composition of weight loss — not just the quantity — is likely to become a differentiating factor in next-generation metabolic therapies.
Pipeline Timeline: What May Arrive When
The following timeline reflects publicly disclosed trial schedules and regulatory filings as of April 2026. All dates are subject to change based on trial outcomes and regulatory review.
- 2026: Orforglipron FDA submission for type 2 diabetes. CagriSema FDA review decision. Additional TRIUMPH Phase 3 readouts for retatrutide. SYNCHRONIZE Phase 3 data expected for survodutide.
- 2026-2027: Retatrutide FDA filing anticipated (pending remaining TRIUMPH data). Orforglipron obesity indication submission likely.
- 2027-2028: Potential FDA approvals for retatrutide and orforglipron. Amycretin Phase 3 data expected.
- 2028-2029: Amycretin market entry possible if Phase 3 succeeds. Muscle-sparing combination therapies may enter Phase 3.
What This Means for the Field
The metabolic drug pipeline is diversifying along several axes simultaneously. Triple agonists like retatrutide are pushing the ceiling of achievable weight loss by engaging additional metabolic pathways. Oral non-peptide compounds like orforglipron are addressing the practical barrier of injection-based delivery. Amylin-based combinations like CagriSema and amycretin are exploiting appetite-regulation pathways distinct from GLP-1. And muscle-sparing adjuncts are beginning to address the quality of weight loss, not just the quantity.
These are not competing narratives. They represent parallel engineering efforts aimed at different constraints in the same clinical problem. The future of metabolic pharmacotherapy may involve selecting from a menu of mechanisms based on individual patient characteristics — metabolic phenotype, comorbidity profile, preference for oral versus injectable administration, and concern about lean mass preservation.
The research is moving quickly. What we know today about these compounds is based on Phase 2 and early Phase 3 data, and late-stage trials can produce unexpected safety signals or efficacy changes. The most responsible approach is to track the data as it emerges without extrapolating beyond what the evidence supports.
Medical Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, and nothing in this content should be interpreted as a recommendation to use any compound discussed. All agents described are investigational and are not FDA-approved for weight management as of April 2026. Do not use any pharmaceutical agent without the direct supervision of a licensed healthcare provider. If you are considering weight-management therapy, consult your physician to discuss options that are appropriate for your individual health status.